Abstract:Background: Multiple systematic reviews explore the effect of phosphodiesterase type 5 (PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific outcomes. However, physicians and policymakers require a holistic approach of this topic. Objective: To summarize the current evidence regarding the efficacy and safety of PDE5 inhibitors for the management of ED through an overview of systematic reviews. Methods: Studies were identified by searching PubMed, Web of Science, Cochrane Library and Scopus databases, as well as sources of grey literature until June 12, 2021 (PROSPERO: CRD42020216754). We considered systematic reviews, meta-analyses or network meta-analyses of randomized trials that provided outcomes about the efficacy and safety of any approved PDE5 inhibitor (avanafil, sildenafil, tadalafil and vardenafil). We constructed forest plots for meta-analytic effects regarding the change in erectile function, adverse events and dropouts after administration of PDE5 inhibitors in the general population and in specific patient groups. Results: We included 23 studies with 154,796 participants and a total of 258 meta-analytic effects. Sildenafil 25 mg [Weighted Mean Difference (WMD): 13.08, 95% Confidence Interval (CI): 10.1-16.06] seemed to be statistically superior to all interventions in improving erectile function compared to placebo, but studies with low-dose sildenafil are lacking. Moreover, comparing among different PDE5 inhibitors, sildenafil 50 mg or sildenafil 100 mg were considered the most effective compounds in the general population. The latter derived, however, predominantly from indirect comparisons among different PDE5 inhibitors. Still, sildenafil 100 mg was associated with more treatment-related adverse events and dropouts. Interestingly, low-dose daily tadalafil may be more effective than high-dose on-demand tadalafil (WMD: 1.24, 95% CI: 0.03-2.44). Furthermore, testosterone and PDE5 inhibitors in patients with ED and hypogonadism seem to further improve symptoms, while the addition of a-blockers in patients with urinary symptoms treated with PDE5 inhibitors does not provide additional benefits (WMD: -0.8, 95% CI: -1.65-0.06). Conclusion: Although the efficacy and safety of PDE5 inhibitors, compared to placebo, is well-documented, the existing evidence comparing different PDE5 inhibitors is low. Therefore, high-quality, head-to-head, trials comparing different PDE5 inhibitors are necessary to determine their ideal dosage and formulation based on their safety and efficacy profile. Systematic Review Registration: PROSPERO, identifier [CRD42020216754].

Research Progress of Effects of PDE5 Inhibitors on Sperm Motility and Fertilizing Capacity

The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Meta-analysis and Systematic Review

Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta-Analysis

Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview

Phosphodiesterase 10A Inhibitor PF-2545920 As a Prospective Agent for the Clinical Promotion of Sperm Motility

PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?

Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction

AB085. Systematic Review and Meta-Analysis of Phosphodiesterase Type 5 Inhibitors for the Treatment of Female Sexual Dysfunction

Efficacy of Phosphodiesterase-5 Inhibitor in Men with Premature Ejaculation: A New Systematic Review and Meta-analysis

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews

Efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation and normal sexual function：a systematic review

Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors

Efficacy of Selective Inhibitors of Phosphodiesterase-5 (PDE-5) for Erectile Dysfunction:A Clinical Evaluation

[Therapeutic Effect of Phosphodiesterase-5 Inhibitor on Pathological Changes of Tunica Albuginea in Erectile Dysfunction: Experiment with Rats].

Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety

[Efficacy and Safety of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction].

Phosphodiesterase-5 Inhibitors Could Be Efficacious In The Treatment Of Erectile Dysfunction After Radiotherapy For Prostate Cancer: A Systematic Review And Meta-Analysis

[The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]

Amnesia for Object Attributes

Influence of Erectile Dysfunction Course on Its Progress and Efficacy of Treatment with Phosphodiesterase Type 5 Inhibitors.

Update of PDE5 Inhibitors As Treatment of ED